No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 15 of the 40 quarters in the window, leaving 25 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 31.2x · 10Y median 29.2x · 55th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:14:39.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Protagonist Therapeutics, Inc. (PTGX) stock was $136.97 as of Oct 6, 2026, 1:10 PM EDT, down 2.60% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +116.1% · 3-year avg +105.4%/yr · 5-year avg +50.9%/yr
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.
Biotechnology · Newark, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
2.43
Revenue Est.
$240.13M
Last Quarter Results
EPS
$2.29
vs Estimate
$1.93
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PTGX | $8.81B | $136.97 | -2.60% | +116.12% | +50.88% | +20.54% | N/A |
| 2ARWR | $8.70B | $61.78 | -0.91% | +72.17% | +0.75% | +23.56% | vs PTGX |
| 3AXSM | $8.99B | $174.68 | -1.36% | +46.93% | +41.40% | +35.76% | vs PTGX |
| 4BRKRP | $9.02B | $449.50 | -3.56% | +62.86% | N/A | N/A | vs PTGX |
| 5KYMR | $8.59B | $104.39 | -4.97% | +89.15% | +12.31% | N/A | vs PTGX |
| 6OSCR | $8.37B | $32.30 | -0.37% | +49.39% | +14.97% | N/A | vs PTGX |
$213.47M
vs Estimate
$198.66M
Consensus Rating
Based on 13 analysts
Average Price Target
$174.69
+27.5% upside
Low
$149.00
Current
$136.97
High
$225.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.72 | $2.43 | $3.63 | 7 |
| Quarter ending Dec 2026 | $-0.36 | $-0.26 | $-0.15 | 6 |
| Quarter ending Mar 2027 | $-0.63 | $-0.14 | $0.02 | 2 |
| Quarter ending Jun 2027 | $-0.15 | $-0.03 | $0.01 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $3.93 | $4.67 | $5.94 | 8 |
| FY 2027 | $-17.34 | $-0.43 | $29.42 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $230.48M | $240.13M | $255.85M | 7 |
| Quarter ending Dec 2026 | $7.30M | $37.89M | $77.46M | 6 |
| Quarter ending Mar 2027 | $5.14M | $48.53M | $184.53M | 3 |
| Quarter ending Jun 2027 | $5.53M | $52.14M | $198.28M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $521.88M | $543.43M | $574.86M | 9 |
| FY 2027 | $97.46M | $192.73M | $284.85M | 9 |
